Preclinical News and Research

RSS
Amgen, Micromet to expand development of BiTE antibodies against solid tumors

Amgen, Micromet to expand development of BiTE antibodies against solid tumors

MSU professor focuses on new formulation for old drug to treat parasitic diseases

MSU professor focuses on new formulation for old drug to treat parasitic diseases

Nature journal publishes landmark genetic study of ovarian cancer

Nature journal publishes landmark genetic study of ovarian cancer

Combination therapy shows promise against HER2-positive metastatic breast cancer

Combination therapy shows promise against HER2-positive metastatic breast cancer

Mesenchymal stem cells protect and heal

Mesenchymal stem cells protect and heal

Autologous adult stem cells reduce frequency of angina episodes

Autologous adult stem cells reduce frequency of angina episodes

InVivo files biopolymer scaffold IDE with FDA to initiate spinal cord injury clinical trial

InVivo files biopolymer scaffold IDE with FDA to initiate spinal cord injury clinical trial

Researchers identify cellular origin of malignant glioma

Researchers identify cellular origin of malignant glioma

Researchers find new molecule that controls pain sensitivity from UVB irradiation

Researchers find new molecule that controls pain sensitivity from UVB irradiation

Natural vitamin E may reduce brain damage after stroke

Natural vitamin E may reduce brain damage after stroke

ICSI study shows strong increase in first trimester pregnancy loss after the age of 38

ICSI study shows strong increase in first trimester pregnancy loss after the age of 38

Small molecule treatment holds promise for Usher syndrome

Small molecule treatment holds promise for Usher syndrome

Lotus Tissue Repair to develop DEB protein replacement therapy with $26 million Series A financing

Lotus Tissue Repair to develop DEB protein replacement therapy with $26 million Series A financing

Study provides novel information about clinical potential of anti-cancer antibiotics

Study provides novel information about clinical potential of anti-cancer antibiotics

Cell Therapeutics to sell $30 million of Preferred Stock and warrants in registered offering

Cell Therapeutics to sell $30 million of Preferred Stock and warrants in registered offering

COIN hosts ‘Risk vs. Reward: Financing Early-Stage, Emerging Technologies’ roundtable event

COIN hosts ‘Risk vs. Reward: Financing Early-Stage, Emerging Technologies’ roundtable event

Acetylon to advance ACY-1215 drug candidate with $27M Series B Preferred equity investment round of financing

Acetylon to advance ACY-1215 drug candidate with $27M Series B Preferred equity investment round of financing

Threshold commences combination Phase 1/2 trial of TH-302 and sunitinib for RCC, GIST and PNET

Threshold commences combination Phase 1/2 trial of TH-302 and sunitinib for RCC, GIST and PNET

Amorfix fiscal 2011 net loss decreases to $3,330,437

Amorfix fiscal 2011 net loss decreases to $3,330,437

Anacor, DNDi and SCYNEXIS complete SCYX-7158 pre-clinical studies for combating sleeping sickness

Anacor, DNDi and SCYNEXIS complete SCYX-7158 pre-clinical studies for combating sleeping sickness

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.